Bliss GVS Pharma (BLISSGVS) Fundamentals 2026 — P/E 36.9x, Revenue Analysis | SniperIQ
Bliss GVS Pharma (BLISSGVS) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹4,688 Crore, trading at ₹448.15 on the BSE. This SniperIQ fundamentals page covers Bliss GVS Pharma's valuation (P/E 36.9x, P/B 4.1x), profitability (net margin 13.9%), revenue (₹927 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Bliss GVS Pharma's market cap?
Bliss GVS Pharma (BLISSGVS) has a market capitalization of approximately ₹4,688 Crore, trading at ₹448.15 on the BSE. Market cap moves with the live share price.
What is Bliss GVS Pharma's P/E ratio?
Bliss GVS Pharma's trailing twelve-month P/E ratio is 36.9x, with a price-to-book (P/B) of 4.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Bliss GVS Pharma?
Bliss GVS Pharma runs a net profit margin of 13.9%, a gross margin of 49.7%, and an operating margin of 12.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Bliss GVS Pharma generate?
Bliss GVS Pharma reported revenue of ₹927 Crore for fiscal year 2026, with net income of ₹129 Crore and earnings per share (EPS) of 12.23. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Bliss GVS Pharma pay a dividend?
Bliss GVS Pharma offers a trailing dividend yield of about 0.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Bliss GVS Pharma financially healthy?
Bliss GVS Pharma carries a debt-to-equity ratio of 0.02x and a current ratio of 4.02x, with a market beta of 1.13. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Bliss GVS Pharma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Bliss GVS Pharma (BLISSGVS) the key facts are: market cap ₹4,688 Crore, P/E 36.9x, revenue ₹927 Crore, 52-week range 118.35-552.9. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Bliss GVS Pharma's full fundamentals live
Get Bliss GVS Pharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.